JP2025503731A5 - - Google Patents

Info

Publication number
JP2025503731A5
JP2025503731A5 JP2024542281A JP2024542281A JP2025503731A5 JP 2025503731 A5 JP2025503731 A5 JP 2025503731A5 JP 2024542281 A JP2024542281 A JP 2024542281A JP 2024542281 A JP2024542281 A JP 2024542281A JP 2025503731 A5 JP2025503731 A5 JP 2025503731A5
Authority
JP
Japan
Prior art keywords
binding domain
cancer
protein complex
terminus
complex according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503731A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/053125 external-priority patent/WO2023140950A1/en
Publication of JP2025503731A publication Critical patent/JP2025503731A/ja
Publication of JP2025503731A5 publication Critical patent/JP2025503731A5/ja
Pending legal-status Critical Current

Links

JP2024542281A 2022-01-18 2022-12-16 Ｃｄ４７／ｐｄ－ｌ１を標的とするタンパク質複合体及びその使用方法 Pending JP2025503731A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263300440P 2022-01-18 2022-01-18
US63/300,440 2022-01-18
PCT/US2022/053125 WO2023140950A1 (en) 2022-01-18 2022-12-16 Cd47/pd-l1-targeting protein complex and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025503731A JP2025503731A (ja) 2025-02-04
JP2025503731A5 true JP2025503731A5 (enExample) 2025-12-23

Family

ID=87348782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542281A Pending JP2025503731A (ja) 2022-01-18 2022-12-16 Ｃｄ４７／ｐｄ－ｌ１を標的とするタンパク質複合体及びその使用方法

Country Status (10)

Country Link
US (1) US20240360219A1 (enExample)
EP (1) EP4466293A4 (enExample)
JP (1) JP2025503731A (enExample)
KR (1) KR20240133694A (enExample)
CN (1) CN118401564A (enExample)
AU (1) AU2022435471A1 (enExample)
CA (1) CA3239434A1 (enExample)
IL (1) IL314210A (enExample)
TW (1) TW202334192A (enExample)
WO (1) WO2023140950A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023146654A1 (en) * 2022-01-31 2023-08-03 Fbd Biologics Limited Engineered pd-1 variants and methods of use thereof
WO2024245380A1 (en) * 2023-05-31 2024-12-05 Fbd Biologics Limited Cd47/pd-l1-targeting protein complex and methods of use thereof
CN121914290A (zh) * 2026-01-30 2026-04-24 北京再青生物科技有限公司 一种靶向pd-l1细胞并串联tgfbr2胞外域、il-2及其受体的融合蛋白及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2504028A4 (en) * 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US8993524B2 (en) * 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
EP3766511A1 (en) * 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
ES2751915T5 (es) * 2014-08-15 2022-12-23 Merck Patent Gmbh Proteínas de fusión de inmunoglobulina con SIRP alfa
EP3197916A2 (en) * 2014-09-25 2017-08-02 Amgen Inc. Protease-activatable bispecific proteins
CN110050000B (zh) * 2017-05-12 2022-07-26 苏州盛迪亚生物医药有限公司 含有TGF-β受体的融合蛋白及其医药用途
CN107857819A (zh) * 2017-07-03 2018-03-30 江苏西迪尔生物技术有限公司 多功能融合蛋白及其应用
WO2019075090A1 (en) * 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
US11673954B2 (en) * 2017-11-17 2023-06-13 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-L1
CA3084626A1 (en) * 2017-12-04 2019-06-13 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
CN112672753B (zh) * 2018-07-09 2025-07-08 普瑞赛格恩公司 融合构建体及其使用方法
BR112022000319A2 (pt) * 2019-07-11 2022-03-15 Kahr Medical Ltd Heterodímeros e métodos de uso dos mesmos
BR112022005114A2 (pt) * 2019-10-04 2022-06-21 Seagen Inc Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
CA3158047A1 (en) * 2019-12-11 2021-06-17 Yunying CHEN Bi-functional antibody against pd-l1 and tgf?
JP7369297B2 (ja) * 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
CN111690070A (zh) * 2020-05-13 2020-09-22 深圳市众循精准医学研究院 一种sPD-1-Fc-sTGFβRII融合蛋白及其应用
CN113773401B (zh) * 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途

Similar Documents

Publication Publication Date Title
CN112154157B (zh) 抗ror1抗体及其用途
JP7041516B2 (ja) 共通軽鎖を有する二重特異性抗体又は抗体混合物
CN107001485B (zh) 蛋白质异二聚体及其用途
JP2021526816A (ja) Ｄｌｌ３−ｃｄ３二重特異性抗体
JP2023549537A5 (enExample)
CN111944050A (zh) 一种抗b7-h3抗体及其应用
JP2023539501A5 (enExample)
KR20230031373A (ko) 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
WO2023174396A1 (zh) 一种新型免疫调节剂的开发和应用
JP2022517920A5 (enExample)
CN106831987B (zh) 一种抗人her2抗体及其编码基因和应用
JP2025535104A (ja) Ｂ７ｈ３／ｐｄｌ１二重特異性抗体およびその医薬組成物ならびにその使用
JP2024540461A (ja) 二重特異性抗体及びその用途
CN110835372B (zh) 一种靶向Frizzled7单克隆抗体及其制备方法与应用
CN120271715A (zh) 抗体及其药物偶联物和用途
US20240101680A1 (en) Antibodies Targeting Integrin Beta-2
EP4717714A1 (en) Anti-pd-1-anti-vegf bispecific antibody, pharmaceutical composition thereof and use thereof
US20250136713A1 (en) Anti-her2 antibodies and methods of use thereof
CN111333732B (zh) 一种靶向人bcma且激活nk细胞的双特异性抗体的制备及其应用
JP2024508597A5 (enExample)
CN116802297A (zh) 抗PD-L1/TGF-β双功能抗体及其用途
RU2024123482A (ru) Белковый комплекс, нацеленный на cd47/pd-l1, и способы его использования
TW202206099A (zh) 藉由併用抗人類Fn14抗體及免疫檢查點抑制劑預防或治療癌症之醫藥組合物及方法
JPWO2016163433A1 (ja) 抗ｆｇｆｒ２抗体と他剤を含む組成物
CN116003599B (zh) 抗人gas6抗体或其抗原结合片段及其应用